Mdnc.Pk
MDNC.PK operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its customers.
Business. MDNC.PK operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its customers.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-09-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MDNC.PK operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its customers.
MDNC.PK maintains a strong liquidity position with a current ratio of 4.27, indicating the company can cover its short-term liabilities more than four times over. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of $877,830 and free cash flow of $2,233,320. The debt-to-equity ratio of 0.22 reflects a conservative capital structure, with long-term debt amounting to $940,280 against total equity of $4,270,830.
In terms of profitability, MDNC.PK demonstrates a return on equity (ROE) of 50.56% and a return on assets (ROA) of 31.72%, both of which are significantly higher than the industry median for medical equipment and supplies. The company's net income of $2,159,470 and operating income of $3,191,500 highlight its strong earnings performance. Gross profit of $4,860,790 further supports the company's ability to maintain healthy margins in a competitive industry.
MDNC.PK's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly in the healthcare services and equipment sector.
The company's growth trajectory is supported by a strong free cash flow and operating cash flow, which provide flexibility for reinvestment or shareholder returns. However, the outlook for the current fiscal year does not include specific numeric deltas for revenue growth, and the next fiscal year's direction remains unquantified in the available data.
The risk assessment for MDNC.PK indicates a low dilution potential, with no significant dilution sources identified in the risk assessment or recent filings. The company's liquidity risk is rated as medium, primarily due to its negative net cash position after subtracting total debt. No major risk factors or dilution events are disclosed in the available documents, suggesting a relatively stable capital structure.
Recent events and filings for MDNC.PK do not include any material disclosures or transcripts that would indicate significant changes in the company's operations or financial position. The absence of recent events suggests a stable and predictable business environment for the company.
- MDNC.PK has a strong liquidity position with a current ratio of 4.27 and a conservative debt-to-equity ratio of 0.22.
- The company's profitability is robust, with a return on equity of 50.56% and a return on assets of 31.72%.
- MDNC.PK's revenue is concentrated in a single business segment, which may increase its exposure to sector-specific risks.
- The company's growth is supported by strong free and operating cash flows, but no specific growth targets are disclosed for the current or next fiscal year.
- The risk assessment indicates a low dilution potential and a medium liquidity risk, with no major risk factors identified in the available data.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- MDNC.PK Market data — financials · 2026-05-28
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2026-02-28 vs 2025-02-28): -61.1%Derived (calculated)
- Capex (YoY) (2026-02-28 vs 2025-02-28): 101.5%Derived (calculated)
- Cost of revenue (YoY) (2026-02-28 vs 2025-02-28): 208.2%Derived (calculated)
- R&D expense (YoY) (2026-02-28 vs 2025-02-28): 264.4%Derived (calculated)
- Operating income (YoY) (2026-02-28 vs 2025-02-28): -65.7%Derived (calculated)
- Operating cash flow (YoY) (2026-02-28 vs 2025-02-28): 3.3%Derived (calculated)
- Net income (YoY) (2026-02-28 vs 2025-02-28): -63.2%Derived (calculated)
- Gross profit (YoY) (2026-02-28 vs 2025-02-28): 5.5%Derived (calculated)
- Revenue (YoY) (2026-02-28 vs 2025-02-28): 6.8%Derived (calculated)
- Net margin (FY 2026-02-28): 8.2%Derived (calculated)
- Gross margin (FY 2026-02-28): 52.7%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
- Capex (annual): USD 1.36KSEC XBRL filing
- Net income (annual): USD 794.5KSEC XBRL filing
- Gross profit (annual): USD 5.13MSEC XBRL filing
- Total operating expenses (annual): USD -4.03MSEC XBRL filing
- Revenue (annual): USD 9.73MSEC XBRL filing
- Operating cash flow (annual): USD 906.8KSEC XBRL filing
- R&D expense (annual): USD 149.86KSEC XBRL filing
- Operating income (annual): USD 1.09MSEC XBRL filing
- Pre-tax income (annual): USD 1.07MSEC XBRL filing
- Cost of revenue (annual): USD 4.6MSEC XBRL filing
- Interest expense (annual): USD 87.59KSEC XBRL filing
- Shareholders' equity (YoY) (2025-11-30 vs 2024-11-30): 94.6%Derived (calculated)